162 related articles for article (PubMed ID: 23426706)
1. Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome.
Xiang S; Hua F; Chen L; Tang Y; Jiang X; Liu Z
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):115-8. PubMed ID: 23426706
[TBL] [Abstract][Full Text] [Related]
2. Anthropometric indices of central obesity how discriminators of metabolic syndrome in Brazilian women with polycystic ovary syndrome.
Costa EC; Sá JC; Soares EM; Lemos TM; Maranhão TM; Azevedo GD
Gynecol Endocrinol; 2012 Jan; 28(1):12-5. PubMed ID: 21958393
[TBL] [Abstract][Full Text] [Related]
3. Optimal waist circumference for prediction of metabolic syndrome in young Korean women with polycystic ovary syndrome.
Oh JY; Sung YA; Lee HJ; Oh JY; Chung HW; Park H
Obesity (Silver Spring); 2010 Mar; 18(3):593-7. PubMed ID: 19763092
[TBL] [Abstract][Full Text] [Related]
4. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome.
Gateva AT; Kamenov ZA
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):161-6. PubMed ID: 22727921
[TBL] [Abstract][Full Text] [Related]
5. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome.
Wiltgen D; Benedetto IG; Mastella LS; Spritzer PM
Hum Reprod; 2009 Jul; 24(7):1726-31. PubMed ID: 19329517
[TBL] [Abstract][Full Text] [Related]
6. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women.
Wehr E; Gruber HJ; Giuliani A; Möller R; Pieber TR; Obermayer-Pietsch B
J Clin Endocrinol Metab; 2011 Jun; 96(6):E986-90. PubMed ID: 21470992
[TBL] [Abstract][Full Text] [Related]
7. Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome.
Abruzzese GA; Cerrrone GE; Gamez JM; Graffigna MN; Belli S; Lioy G; Mormandi E; Otero P; Levalle OA; Motta AB
Horm Metab Res; 2017 Jan; 49(1):23-29. PubMed ID: 27571188
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of metabolic syndrome in reproductive-aged polycystic ovary syndrome Thai women.
Indhavivadhana S; Wongwananuruk T; Rattanachaiyanont M; Techatraisak K; Leerasiri P; Tanmahasamut P; Popijan M
J Med Assoc Thai; 2010 Jun; 93(6):653-60. PubMed ID: 20572369
[TBL] [Abstract][Full Text] [Related]
9. Lipid accumulation product and insulin resistance in Iranian PCOS prevalence study.
Hosseinpanah F; Barzin M; Erfani H; Serahati S; Ramezani Tehrani F; Azizi F
Clin Endocrinol (Oxf); 2014 Jul; 81(1):52-7. PubMed ID: 23844634
[TBL] [Abstract][Full Text] [Related]
10. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome.
Cussons AJ; Watts GF; Burke V; Shaw JE; Zimmet PZ; Stuckey BG
Hum Reprod; 2008 Oct; 23(10):2352-8. PubMed ID: 18635531
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset.
Espinós-Gómez JJ; Rodriguez-Espinosa J; Ordóñez-Llanos J; Calaf-Alsina J
Gynecol Endocrinol; 2012 Apr; 28(4):264-8. PubMed ID: 21962027
[TBL] [Abstract][Full Text] [Related]
12. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population.
Taverna MJ; Martínez-Larrad MT; Frechtel GD; Serrano-Ríos M
Eur J Endocrinol; 2011 Apr; 164(4):559-67. PubMed ID: 21262912
[TBL] [Abstract][Full Text] [Related]
13. Lipid Accumulation Product: a Simple and Accurate Index for Predicting Metabolic Syndrome in Patients with Adult Growth Hormone Deficiency.
Chan L; Xue H; Xiaoya Z; Jiajia X; Wei R; Linman L; Qing L; Lan L
Exp Clin Endocrinol Diabetes; 2016 Apr; 124(4):220-4. PubMed ID: 27123781
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions.
Bhattacharya SM
Gynecol Endocrinol; 2010 Jul; 26(7):516-20. PubMed ID: 20540665
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and risk of metabolic syndrome in adolescent Indian girls with polycystic ovary syndrome using the 2009 'joint interim criteria'.
Bhattacharya SM; Jha A
J Obstet Gynaecol Res; 2011 Oct; 37(10):1303-7. PubMed ID: 21535308
[TBL] [Abstract][Full Text] [Related]
16. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria.
Goverde AJ; van Koert AJ; Eijkemans MJ; Knauff EA; Westerveld HE; Fauser BC; Broekmans FJ
Hum Reprod; 2009 Mar; 24(3):710-7. PubMed ID: 19095675
[TBL] [Abstract][Full Text] [Related]
17. The metabolic syndrome in young Korean women with polycystic ovary syndrome.
Park HR; Choi Y; Lee HJ; Oh JY; Hong YS; Sung YA
Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S243-6. PubMed ID: 17610984
[TBL] [Abstract][Full Text] [Related]
18. Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome.
Božić-Antić I; Ilić D; Bjekić-Macut J; Bogavac T; Vojnović-Milutinović D; Kastratovic-Kotlica B; Milić N; Stanojlović O; Andrić Z; Macut D
Eur J Endocrinol; 2016 Dec; 175(6):551-560. PubMed ID: 27634940
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
[TBL] [Abstract][Full Text] [Related]
20. Association between the polycystic ovary syndrome and the metabolic syndrome in Puerto Rico.
Rabelo Acevedo M; Vick MR
P R Health Sci J; 2005 Sep; 24(3):203-6. PubMed ID: 16329683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
